The optimal duration of dual antiplatelet therapy (DAPT) in patients with ischaemic cardiovascular (CV) disease is still debated. Previous meta-analyses reported conflicting results about prolonged DAPT on mortality and major CV events. Aim of this study was to assess the effects of prolonged vs. no/short-term DAPT on myocardial infarction (MI), stroke, bleeding, and mortality.
Efficacy and safety of prolonged dual antiplatelet therapy: a meta-analysis of 15 randomized trials enrolling 85 265 patients / Savarese, Gianluigi; Savonitto, Stefano; Lund, Lars H; Paolillo, Stefania; Marciano, Caterina; Dellegrottaglie, Santo; Parente, Antonio; Trimarco, Bruno; Luscher, Thomas F; PERRONE FILARDI, Pasquale. - In: EUROPEAN HEART JOURNAL. CARDIOVASCULAR PHARMACOTHERAPY. - ISSN 2055-6845. - (2016), p. pvw011. [10.1093/ehjcvp/pvw011]
Efficacy and safety of prolonged dual antiplatelet therapy: a meta-analysis of 15 randomized trials enrolling 85 265 patients
SAVARESE, GIANLUIGI;PAOLILLO, STEFANIA;MARCIANO, CATERINA;DELLEGROTTAGLIE, SANTO;PARENTE, ANTONIO;TRIMARCO, BRUNO;PERRONE FILARDI, PASQUALE
2016
Abstract
The optimal duration of dual antiplatelet therapy (DAPT) in patients with ischaemic cardiovascular (CV) disease is still debated. Previous meta-analyses reported conflicting results about prolonged DAPT on mortality and major CV events. Aim of this study was to assess the effects of prolonged vs. no/short-term DAPT on myocardial infarction (MI), stroke, bleeding, and mortality.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
